BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weinberger R, van der Linden M, Imöhl M, von Kries R. Vaccine effectiveness of PCV13 in a 3 + 1 vaccination schedule. Vaccine 2016;34:2062-5. [DOI: 10.1016/j.vaccine.2016.02.043] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Lecrenier N, Marijam A, Olbrecht J, Soumahoro L, Nieto Guevara J, Mungall B. Ten years of experience with the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine ( Synflorix ) in children. Expert Review of Vaccines 2020;19:247-65. [DOI: 10.1080/14760584.2020.1738226] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Izurieta P, Bahety P, Adegbola R, Clarke C, Hoet B. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution. Expert Review of Vaccines 2018;17:479-93. [DOI: 10.1080/14760584.2018.1413354] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
3 Mclaughlin JM, Jiang Q, Gessner BD, Swerdlow DL, Sings HL, Isturiz RE, Jodar L. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis. Vaccine 2019;37:6310-6. [DOI: 10.1016/j.vaccine.2019.08.059] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
4 Adebanjo TA, Pondo T, Yankey D, Hill HA, Gierke R, Apostol M, Barnes M, Petit S, Farley M, Harrison LH, Holtzman C, Baumbach J, Bennett N, McGuire S, Thomas A, Schaffner W, Beall B, Whitney CG, Pilishvili T. Pneumococcal Conjugate Vaccine Breakthrough Infections: 2001-2016. Pediatrics 2020;145:e20190836. [PMID: 32054822 DOI: 10.1542/peds.2019-0836] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
5 Nieto Guevara J, Borys D, DeAntonio R, Guzman-Holst A, Hoet B. Interchangeability between pneumococcal conjugate vaccines for pediatric use: a systematic literature review. Expert Rev Vaccines 2020;19:1011-22. [PMID: 31751159 DOI: 10.1080/14760584.2019.1688148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jayasinghe S, Chiu C, Quinn H, Menzies R, Gilmour R, McIntyre P. Effectiveness of 7- and 13-Valent Pneumococcal Conjugate Vaccines in a Schedule Without a Booster Dose: A 10-Year Observational Study. Clin Infect Dis 2018;67:367-74. [PMID: 29471432 DOI: 10.1093/cid/ciy129] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
7 Sohn S, Hong K, Chun BC. Evaluation of the effectiveness of pneumococcal conjugate vaccine for children in Korea with high vaccine coverage using a propensity score matched national population cohort. International Journal of Infectious Diseases 2020;93:146-50. [DOI: 10.1016/j.ijid.2020.01.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Varghese L, Talbot L, Govender A, Zhang XH, Mungall BA. A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand. Appl Health Econ Health Policy 2018;16:331-45. [PMID: 29633160 DOI: 10.1007/s40258-018-0387-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mukerji R, Briles DE. New Strategy Is Needed to Prevent Pneumococcal Meningitis. Pediatr Infect Dis J 2020;39:298-304. [PMID: 32032170 DOI: 10.1097/INF.0000000000002581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
10 Guevara JN, Izurieta P, Hoet B. Response to: Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A? Expert Rev Vaccines 2018;17:283-4. [PMID: 29611439 DOI: 10.1080/14760584.2018.1459247] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Wasserman M, Sings HL, Jones D, Pugh S, Moffatt M, Farkouh R. Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Review of Vaccines 2018;17:71-8. [DOI: 10.1080/14760584.2018.1409116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
12 Perniciaro S, Imöhl M, Fitzner C, van der Linden M. Regional variations in serotype distribution and vaccination status in children under six years of age with invasive pneumococcal disease in Germany. PLoS One 2019;14:e0210278. [PMID: 30625215 DOI: 10.1371/journal.pone.0210278] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
13 Sings HL, De Wals P, Gessner BD, Isturiz R, Laferriere C, McLaughlin JM, Pelton S, Schmitt HJ, Suaya JA, Jodar L. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies. Clin Infect Dis 2019;68:2135-43. [PMID: 30357326 DOI: 10.1093/cid/ciy920] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 18.0] [Reference Citation Analysis]
14 Izurieta P, Nieto Guevara J. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease. Hum Vaccin Immunother 2021;:1-8. [PMID: 33605846 DOI: 10.1080/21645515.2021.1872341] [Reference Citation Analysis]
15 Agudelo CI, Deantonio R, Castañeda E. Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean 2010–2015: A systematic review and a time series analysis. Vaccine 2018;36:4861-74. [DOI: 10.1016/j.vaccine.2018.06.068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
16 De Wals P, Lefebvre B, Deceuninck G, Longtin J. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec. Vaccine 2018;36:421-6. [DOI: 10.1016/j.vaccine.2017.11.054] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
17 Polkowska A, Rinta-Kokko H, Toropainen M, Palmu AA, Nuorti JP. Long-term population effects of infant 10-valent pneumococcal conjugate vaccination on pneumococcal meningitis in Finland. Vaccine 2021;39:3216-24. [PMID: 33934915 DOI: 10.1016/j.vaccine.2021.02.030] [Reference Citation Analysis]
18 Mungall BA, Hoet B, Nieto Guevara J, Soumahoro L. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines 2021. [PMID: 34882050 DOI: 10.1080/14760584.2022.2012455] [Reference Citation Analysis]
19 Lapidot R, Shea KM, Yildirim I, Cabral HJ, Pelton SI, Department Of Public Health TM. Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts. Pathogens 2020;9:E396. [PMID: 32455770 DOI: 10.3390/pathogens9050396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
20 Mungall BA, Nieto J, Soumahoro L, Hoet B. Letter to the editor to: Isturiz et al. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert review of vaccines 2017;16(10):1007-27. Expert Rev Vaccines 2018;17:665-8. [PMID: 30067110 DOI: 10.1080/14760584.2018.1506205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Zhang T, Zhang J, Shao X, Feng S, Xu X, Zheng B, Liu C, Dai Z, Jiang Q, Gessner BD, Chen Q, Zhu J, Luan L, Tian J, Zhao G. Effectiveness of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia among children in China, an observational cohort study. Vaccine 2021;39:4620-7. [PMID: 34253417 DOI: 10.1016/j.vaccine.2021.06.075] [Reference Citation Analysis]
22 Suwantika AA, Zakiyah N, Kusuma ASW, Abdulah R, Postma MJ. Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia. Vaccines (Basel) 2020;8:E233. [PMID: 32443523 DOI: 10.3390/vaccines8020233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
23 Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert RR, Gessner B, Jodar L. Response to Mungall et al. letter to the editor on Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert review of vaccines 2017;16(10):1007-27. Expert Rev Vaccines 2018;17:669-71. [PMID: 30071169 DOI: 10.1080/14760584.2018.1506207] [Reference Citation Analysis]
24 Lu CY, Chung CH, Huang LM, Kruger E, Tan SC, Zhang XH, Chiu NC. Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan. Cost Eff Resour Alloc 2020;18:30. [PMID: 32874139 DOI: 10.1186/s12962-020-00225-9] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]